BioSpace News Archive

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced the advancement to the final dose level in its ongoing clinical trial of CRV431, a Phase 1b multiple ascending dose (“MAD”) study.

Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting (“AGM”).

Orexo AB, announces positive results from its human pharmacokinetic study of OX125.

Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.

Oncopeptides AB announces that the Company submits a New Drug Application to the U.S. FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.

IRRAS AB, a commercial stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, provided an update on the launch of its IRRAflow® and Hummingbird ICP Monitoring product lines during the evolving global COVID-19 pandemic.

Guardion Health Sciences, Inc. announced that it has completed shipment of Astramern to Astramune Sdn Bhd, a subsidiary of Ho Wah Genting Berhad, a Malaysian company listed on the Malaysian Stock Exchange.

The EndBrainCancer Initiative announced that GT Medical Technologies, manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI’s roster of corporate partners.

2020 Fortune/IBM Watson Health 100 Top Hospitals and 15 Top Health Systems Lists Published Today by Fortune

ChromaDex shares new preclinical and clinical findings revealing potential of Niagen® across a variety of health conditions, paving the way for further clinical research